Loading patent…
AssigneeInstitute of Basic Medical Sciences, Chinese Academy of Medical Sciences
InventorsJing Wang, Tiantian Zhang, Xianmei Qi, Xiaona Li
Estimating the term…
The present disclosure provides use of an FcγRIII inhibitor for treating pulmonary fibrosis, and belongs to the technical field of biomedicine. Results indicate that FcγRIII mediates macrophage phagocytosis of silica particles, FcγRIII knockout can effectively relieve pulmonary inflammatory response and fibrotic lesions in mice with silicosis, and further intratracheal administration of an anti-FcγRIII antibody significantly delays disease progression of mice at fibrosis phase. Therefore, the present disclosure first sets forth that the FcγRIII inhibitors can be used for treating pulmonary fibrosis, which is of importance to the screening of new drugs and provides a new idea for treatment of pulmonary fibrosis.
A composition for treating pulmonary fibrosis, comprising an active ingredient and pharmaceutically acceptable carriers, wherein the active ingredient is an shRNA plasmid wherein a functional sequence for knockdown in the shRNA plasmid is SEQ ID NO:
Dependencies are inferred from the claim text.